Patients treated with Benicar in BeniVICTOR study experienced significantly greater blood pressure reductions and higher goal attainment rates than patients treated with Cozaar after 8 weeks.
Actelion Ltd announced that the U.S. Food and Drug Administration has approved additional in-use conditions for administration of Veletri, an improved formulation of epoprostenol.
Geron says GE Healthcare is now selling a human cardiomyocyte-based toxicology screening product the companies developed together.
An American and two Japanese scientists won the Nobel Prize in chemistry for finding new ways to bond carbon atoms together, methods now widely used to make medicines and even slimmed-down computer screens.
The Food and Drug Administration posted a warning letter on its website, outlining more than a half-dozen quality-control problems uncovered by inspectors on a routine visit to Gilead's San Dimas, Calif., facility.
Novartis AG said it will take a charge of $590 million during the third quarter as it discontinues development of a potential hepatitis C drug and an antifungal product.
A federal investigation into Allergan Inc.'s misleading marketing of its wrinkle-smoothing Botox medication is over after a judge in Georgia approved the pharmaceutical firm's decision to pay $600 million and plead guilty to misbranding the product.
Pfizer Inc. said it is reviewing its strategic alternatives for its Capsugel business unit, which makes hard capsules used to deliver medication.
Johnson & Johnson said it is buying Crucell N.V. for about $2.41 billion in a move that will boost the American health care company's vaccine business.
Thermo Fisher Scientific Inc. has introduced the Nunclon Vita stem cell culture surface. The energy-treated polystyrene surface enables direct attachment, colony formation, and growth of human embryonic stem cells and induced pluripotent stem cells.
GE Healthcare announces the availability of human cardiomyocytes that provide a more readily available and biologically-relevant alternative to current cell models and primary cells used in drug discovery and predictive toxicity testing.
TepoFlex biocontainers provide secure, robust fluid handling options. TepoFlex polyethylene-based biocontainers are available in 2D end-ported designs from 250 mL to 20 L and 2D face-ported designs from 5 L-200 L.
Isogenica Ltd, announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of Novabiotic’s anti-infective peptide technology platform.
Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd. to identify small molecule modulators of various protein-protein interaction targets.
Onconova Therapeutics, Inc. announced agreement with the FDA regarding an SPA for the design of a pivotal Phase 3 trial for Estybon as monotherapy in patients with myelodysplastic syndromes, diseases affecting the production of healthy blood cells.